First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide

The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma

(2021) Shigeru YAMAGUCHI et al.   Journal of Neurosurgical Sciences

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Insular primary glioblastomas with IDH mutations: Clinical and biological specificities

(2017) Nobuhiro Hata et al.   NEUROPATHOLOGY

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

(2017) Nobuhiro Hata et al.   OncoTargets and Therapy

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

(2016) Olivier L. Chinot et al.   NEURO-ONCOLOGY

A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology

(2016) Ryusuke Hatae et al.   NEUROPATHOLOGY

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

(2016) Hideyuki Arita et al.   Acta Neuropathologica Communications

Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data

(2016) Ryusuke Hatae et al.   PLoS One

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

(2015) Thomas Sandmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for glioblastoma

(2015) Yoshitaka Narita   Therapeutics and Clinical Risk Management

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas

(2014) Matthias Simon et al.   NEURO-ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era

(2014) Mitchell S. Wachtel et al.   Cancer Medicine

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis

(2013) Derek R. Johnson et al.   CANCER

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue

(2011) Yukie Araki et al.   Brain Tumor Pathology

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE